We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

218 hedge funds and large institutions have $3.68B invested in Neurocrine Biosciences in 2017 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 80 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $3.27B → $3.68B (+$417M)

3% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 37

0.51% more ownership

Funds ownership: 97.13% → 97.64% (+0.51%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

3% less funds holding

Funds holding: 225 → 218 (-7)

10% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 80

39% less call options, than puts

Call options by funds: $12.3M | Put options by funds: $20.3M

Holders
218
Holders Change
-7
Holders Change %
-3.11%
% of All Funds
5.43%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
38
Increased
72
Reduced
80
Closed
37
Calls
$12.3M
Puts
$20.3M
Net Calls
-$8.01M
Net Calls Change
-$6.53M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$214M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$87.4M
3
JHIU
Janus Henderson Investors US
Colorado
+$85.8M
4
Goldman Sachs
Goldman Sachs
New York
+$42.7M
5
Citadel Advisors
Citadel Advisors
Florida
+$30.7M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$80M
2
O
OrbiMed
New York
-$72.3M
3
Millennium Management
Millennium Management
New York
-$51.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$39.4M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$26.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Russell Investments Group
126
Russell Investments Group
United Kingdom
$1.07M -$102K -2,391 -9%
Marshall Wace
127
Marshall Wace
United Kingdom
$1.06M -$14M -326,954 -93%
JMPWA
128
JP Morgan Private Wealth Advisors
California
$1.02M +$9.9K +231 +1%
AL
129
Airain Ltd
Guernsey
$967K +$957K +22,341 New
PI
130
Putnam Investments
Massachusetts
$962K -$219K -5,121 -19%
D.E. Shaw & Co
131
D.E. Shaw & Co
New York
$958K -$6.31M -147,281 -87%
AR
132
Advisory Research
Illinois
$943K -$947K -22,112 -50%
AG
133
Aperio Group
California
$932K -$106K -2,479 -10%
PCM
134
Prelude Capital Management
New York
$889K +$158K +3,699 +22%
TAM
135
Tocqueville Asset Management
New York
$867K -$197K -4,600 -19%
Schroder Investment Management Group
136
Schroder Investment Management Group
United Kingdom
$856K +$14.4K +335 +2%
HI
137
Handelsinvest Investeringsforvaltning
Denmark
$853K +$214K +5,000 +34%
State of Wisconsin Investment Board
138
State of Wisconsin Investment Board
Wisconsin
$844K -$1.27M -29,735 -60%
Two Sigma Advisers
139
Two Sigma Advisers
New York
$801K – – –
FAM
140
Fred Alger Management
New York
$753K -$1.39M -32,489 -65%
WC
141
Woodstock Corp
Massachusetts
$718K – – –
Canada Pension Plan Investment Board
142
Canada Pension Plan Investment Board
Ontario, Canada
$714K +$206K +4,800 +41%
URS
143
Utah Retirement Systems
Utah
$680K – – –
SSA
144
Schonfeld Strategic Advisors
New York
$664K +$656K +15,320 New
Capstone Investment Advisors
145
Capstone Investment Advisors
New York
$662K +$656K +15,307 New
BNP Paribas Financial Markets
146
BNP Paribas Financial Markets
France
$635K +$81K +1,890 +15%
Nomura Asset Management
147
Nomura Asset Management
Japan
$633K – – –
N
148
Nuveen
North Carolina
$626K +$32.7K +763 +6%
Balyasny Asset Management
149
Balyasny Asset Management
Illinois
$600K +$594K +13,856 New
VKH
150
Virtu KCG Holdings
New York
$557K -$615K -14,358 -53%
4 5
6
7 8

NBIX Hedge Fund Activity: Q1 2017 in Review

218 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2017, worth a combined $3.68B — up 13% from $3.27B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new NBIX positions and 37 closed out — a net gain of 1 holder — while 72 added to existing stakes and 80 trimmed.

The largest buyer was BlackRock, adding an estimated $214M. The largest seller was T. Rowe Price Associates, cutting an estimated $80M.

  • 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2017, down from 225 in Q4 2016.
  • Funds reported $3.68B of Neurocrine Biosciences stock for Q1 2017, up 13% quarter-over-quarter.
  • 38 funds opened new Neurocrine Biosciences positions in Q1 2017 and 37 closed out, a net change of +1 holder.
  • The largest Neurocrine Biosciences buyer in Q1 2017 was BlackRock, an estimated $214M added.
  • The largest Neurocrine Biosciences seller in Q1 2017 was T. Rowe Price Associates, an estimated $80M sold.

Based on aggregated 13F filings for Q1 2017.